{
    "nct_id": "NCT06049134",
    "official_title": "Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy",
    "inclusion_criteria": "1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.\n2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.\n3. Patients who are at least 18 years of age.\n4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.\n2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.\n3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson.\n4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)",
    "miscellaneous_criteria": ""
}